文献速递临床试验与 GCP流行病学与生物统计

单剂利福喷丁用于麻风患者家庭接触者

Single-Dose Rifapentine in Household Contacts of Patients with Leprosy.
PubMed 文献 · N Engl J Med · 2023-01-01

在中国西南地区开展的整群随机对照试验中,7450名麻风患者家庭接触者被分为单剂利福喷丁组、单剂利福平组和对照组,随访4年。利福喷丁组4年累积发病率为0.09%,显著低于对照组的0.55%(累积发病率比0.16,P=0.02);利福平组与对照组无显著差异;未观察到严重不良事件。

要点

  • 单剂利福喷丁组4年累积发病率为0.09%,对照组为0.55%,利福喷丁组较对照组降低84%。
  • 单剂利福平组累积发病率为0.33%,与对照组相比无显著差异(P=0.23)。
  • 研究期间未观察到严重不良事件。

核心结论

  • 在麻风患者家庭接触者中,单剂利福喷丁组的4年累积发病率低于无干预对照组。

研究设计与样本

  • 整群随机对照试验,在中国西南地区的县或区(共207个整群)中开展,纳入7450名麻风患者家庭接触者。
  • 整群被随机分配到三组:单剂利福喷丁组68个整群(2331名接触者)、单剂利福平组71个整群(2760名接触者)、对照组68个整群(2359名接触者,无干预)。
  • 主要结局为家庭接触者4年累积麻风发病率。

主要发现

  • 4年随访期间共发生24例新发麻风病例:利福喷丁组2例,利福平组9例,对照组13例。
  • 利福喷丁组4年累积发病率为0.09%(95%CI 0.02至0.34),利福平组为0.33%(95%CI 0.17至0.63),对照组为0.55%(95%CI 0.32至0.95)。
  • 意向性治疗分析中,利福喷丁组累积发病率较对照组降低84%(累积发病率比0.16;多重校正95%CI 0.03至0.87;P=0.02)。
  • 意向性治疗分析中,利福平组与对照组累积发病率无显著差异(累积发病率比0.59;多重校正95%CI 0.22至1.57;P=0.23)。
  • 符合方案分析中,累积发病率利福喷丁组为0.05%,利福平组为0.19%,对照组为0.63%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have suggested that a single dose of rifampin has protective effects against leprosy in close contacts of patients with the disease. Rifapentine was shown to have greater bactericidal activity against Mycobacterium leprae than rifampin in murine models of leprosy, but data regarding its effectiveness in preventing leprosy are lacking. METHODS: We conducted a cluster-randomized, controlled trial to investigate whether single-dose rifapentine is effective in preventing leprosy in household contacts of patients with leprosy. The clusters (counties or districts in Southwest China) were assigned to one of three trial groups: single-dose rifapentine, single-dose rifampin, or control (no intervention). The primary outcome was the 4-year cumulative incidence of leprosy among household contacts. RESULTS: A total of 207 clusters comprising 7450 household contacts underwent randomization; 68 clusters (2331 household contacts) were assigned to the rifapentine group, 71 (2760) to the rifampin group, and 68 (2359) to the control group. A total of 24 new cases of leprosy occurred over the 4-year follow-up, for a cumulative incidence of 0.09% (95% confidence interval [CI], 0.02 to 0.34) with rifapentine (2 cases), 0.33% (95% CI, 0.17 to 0.63) with rifampin (9 cases), and 0.55% (95% CI, 0.32 to 0.95) with no intervention (13 cases). In an intention-to-treat analysis, the cumulative incidence in the rifapentine group was 84% lower than that in the control group (cumulative incidence ratio, 0.16; multiplicity-adjusted 95% CI, 0.03 to 0.87; P = 0.02); the cumulative incidence did not differ significantly between the rifampin group and the control group (cumulative incidence ratio, 0.59; multiplicity-adjusted 95% CI, 0.22 to 1.57; P = 0.23). In a per-protocol analysis, the cumulative incidence was 0.05% with rifapentine, 0.19% with rifampin, and 0.63% with no intervention. No severe adverse events were observed. CONCLUSIONS: The incidence of leprosy among household contacts over 4 years was lower with single-dose rifapentine than with no intervention. (Funded by the Ministry of Health of China and the Chinese Academy of Medical Sciences; Chinese Clinical Trial Registry number, ChiCTR-IPR-15007075.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Wang L, Wang H, Yan L, et al. Single-Dose Rifapentine in Household Contacts of Patients with Leprosy. N Engl J Med. 2023. PMID: 37195940. doi:10.1056/NEJMoa2205487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。